A predictable loss of renal perfusion, glomerular filtration rate and many of the kidneys' functions -- including the ability to handle sodium -- occurs with increasing age. Hypertension, which is sensitive to sodium intake, also increases in frequency with increasing age. This study is designed to explore the responsible mechanisms for the limited ability of the aging kidney to handle salt, and its relation to the hypertension. Our first hypothesis is that a functional element contributes to the loss of renal perfusion and to the limitation of sodium handling with increasing age. Our second hypothesis is that the intrarenal generation of AII, prompted by afferent arteriolar organic lesions or an increasing frequency of glomerular obsolescence, contributes to a number of the abnormal features of aging including renal vasoconstriction, limited sodium handling, renin suppression, and a limited natriuretic response to atrial natriuretic peptide. Our third hypothesis, based on the first two, is that angiotensin converting enzyme inhibition will increase renal perfusion, restore more normal sodium handling, restore the kidneys' response to atrial natriuretic peptide and prevent the hypertension. Central to our approach is the application of proven methods to provide a rigorous assessment of steady state sodium balance and to assess the determinants of sodium balance in humans. Successful completion of these protocols will provide insight into the pathogenesis of many of the features of aging and a more rational approach to prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG000599-17
Application #
3745515
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Elahi, Dariush; Ruff, Dennis A; Carlson, Olga D et al. (2016) Does GLP-1 suppress its own basal secretion? Endocr Res 41:16-20
Elahi, Dariush; Angeli, Franca S; Vakilipour, Amin et al. (2014) GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs. Peptides 59:20-4
Ahmed, Sofia B; Bentley-Lewis, Rhonda; Hollenberg, Norman K et al. (2009) A comparison of prediction equations for estimating glomerular filtration rate in pregnancy. Hypertens Pregnancy 28:243-55
Abu-Hamdah, Rania; Rabiee, Atoosa; Meneilly, Graydon S et al. (2009) Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94:1843-52
Moore, T J; Rich, G; McKnight, J A et al. (1996) Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril. Am J Hypertens 9:54-60
Hollenberg, N K; Moore, T J (1994) Age and the renal blood supply: renal vascular responses to angiotensin converting enzyme inhibition in healthy humans. J Am Geriatr Soc 42:805-8
Allan, D R; McKnight, J A; Kifor, I et al. (1994) Converting enzyme inhibition and renal tissue angiotensin II in the rat. Hypertension 24:516-22
Bauer, K A; Kass, B L; ten Cate, H et al. (1990) Factor IX is activated in vivo by the tissue factor mechanism. Blood 76:731-6
Lee, J K; Gordon, P R; Stall, G M et al. (1989) Phenolic and tyrosyl ring iodothyronine deiodination by the Caco-2 human colon carcinoma cell line. Metabolism 38:1154-61
Bauer, K A; Weiss, L M; Sparrow, D et al. (1987) Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest 80:1527-34